58 Results
Sort By:
Published on November 10, 2016
Scientists at Stanford University School of Medicine have just described in a new study how sequencing minute bits of DNA circulating in the blood of lymphoma patients can accurately identify the cancer subtype and pinpoint mutations that might cause drug resistance. The findings from this new study were published recently…
Published on June 21, 2024
Patients with chronic lymphoblastic leukemia (CLL) and non-Hodgkin lymphoma (NHL) were less likely to experience severe infection if they received frequent testing for immunoglobulin G (IgG)—proteins in the immune system that are at low levels in patients with these blood cancers. The new research, published today in the journal Blood…
Published on July 6, 2021
A little more than three months after it raised $115 million in a Series C financing round, Caribou Biosciences late last week filed for an initial public offering whose size has not yet been determined, though the company’s S-1 registration statement filed with the U.S. Securities and Exchange Commission, included…
Published on November 13, 2024
Adding the antibody therapy pembrolizumab to standard care for people with soft tissue sarcoma can significantly improve survival in these patients according to new research. The study was led by the University Health Network in Toronto and published in The Lancet. It showed that disease-free survival was improved by 39%…
Published on July 24, 2024
A research study led by the University of Kansas suggests that the FDA-mandated monitoring period of diffuse large B-cell non-Hodgkin lymphoma patients receiving chimeric antigen receptor (CAR)-T cell therapy could be halved without harm to patients. Writing in the journal Blood Advances, first author Nausheen Ahmed, a researcher and hematologist…
Published on July 22, 2024
Blood proteins may be better than clinical information at determining a person’s risk of developing 67 diseases within the next 10 years, according to information collected through the UK Biobank. The findings demonstrate how thousands of proteins measured in a single blood sample can predict the onset of diverse diseases.…
Published on April 17, 2024
As it expands from oncology into autoimmune disease, Cullinan Therapeutics (formerly Cullinan Oncology) yesterday announced a $280 million private placement. The company’s lead compound is now CLN-978 for systemic lupus erythematosus (SLE), which it believes has the potential to be a safe, first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases. “Today’s…
Published on January 19, 2024
In a crucial Phase I/II trial, researchers at The University of Texas MD Anderson Cancer Center have reported significant success in treating patients with relapsed or refractory B-cell malignancies using cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19. The findings, published in Nature Medicine, show…
Published on October 25, 2023
Adding immunotherapy to chemotherapy almost doubled survival in patients with an advanced type of bladder cancer, in the first of its kind trial reported in The New England Journal of Medicine and at the annual meeting of the European Society for Medical Oncology (ESMO). The multicenter, international study was co-led by Mount Sinai…
Published on August 9, 2023
Three therapeutic regulatory approvals in less than a year signal that the promise of the human microbiome may finally be paying off. All of the approved therapies focus on treating recurrent Clostridium difficile infection, but what is next for the field? With promising oncology-related trial results from a number of…
Published on June 5, 2023
After decades of research, cell and gene therapies are gaining traction in the biotech industry. Here are five investor-favored private startups with products already in clinical development. While conventional medications are often effective at controlling symptoms or modifying a disease, there are many conditions where their benefits are limited, such…
Published on May 30, 2023
Cell and gene therapy have surprisingly long histories. Cell therapy has existed in the form of bone marrow transplant, used to treat cancers and other conditions, since the late 1950’s, although it only came to prominence with the approval of the first chimeric antigen receptor (CAR) T-cell cancer therapies (Kymriah…
Published on February 8, 2023
Viruses have evolved with humans for millions of years, so it’s no surprise they’ve evolved tricks to evade our natural, or innate, immune responses. Unfortunately, it’s often unclear what these tricks are. But now, thanks to researchers at the University of North Carolina (UNC) School of Medicine, one of these…
Published on October 14, 2022
Recent research demonstrating how important the human microbiome is for maintaining good health has led to the founding of many biotech companies hoping to create microbiome-based therapeutics. These five biotech companies all have candidates in clinical trials and are primed to be among the first to receive market approval. The…
Published on August 9, 2022
Research led by Tel Aviv University and the University of Lisbon has identified a small molecule inhibitor which may be a more accessible and effective alternative to anti-PD-1/PD-L1 immunotherapy antibodies already being used to treat a range of cancers. Inhibiting programmed cell death protein 1 (PD1) and the PD-ligand 1…